Study details
Enrolling now
Cytotoxic T Lymphocytes for Treating Malignancies With BK and/or JC Virus
M.D. Anderson Cancer Center
NCT IDNCT02479698ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
100
Study length
about 12 years
Ages
All ages
Locations
1 site in TX
What this study is about
This trial is testing if donor cytotoxic T lymphocytes can help treat patients with malignancies that have BK and/or JC virus. Cytotoxic T lymphocytes are made from donated blood cells grown in a lab to kill viruses, potentially offering an effective treatment option for these specific cancers.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Laboratory Biomarker Analysis
- 2.Receive Allogeneic BK-specific Cytotoxic T-lymphocytes
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Incidence of adverse events
Secondary: Overall survival
Body systems
Oncology, Immune, Infectious